ASSESSMENT THE EFFICACY AND SAFETY OF POLYNUCLEOTIDE INJECTION FOR PREVENTING POST-SURGICAL SCARS: A RANDOMIZED, CONTROLLED TRIAL

EFFICACY AND SAFETY OF POLYNUCLEOTIDE INJECTION FOR PREVENTING POST-SURGICAL SCARS: A RANDOMIZED, CONTROLLED TRIAL

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250122002

Enrollment

Registered

2025-01-22

Start date

2025-06-04

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inclusion criteria (1) Immediate post excision patient, size more than 2 cm, aged upper 18 years (2) Healthy individual (3) Capable to visit at OPD and follow the method (4) Agree with informed consent (5) Fitzpatrick skin type III-IV Exclusion criteria (1) Allergic to Sodium polynucleotide (2) Using NSIAD, anticoagulants, immunosuppressive drugs (3) Phobia from injection (4) The presence of inflammation or infection on the skin around the site of the injection (5) Pregnancy (6) N

Interventions

20% Sodium Polynucleotide Intradermal injection,No treatment

Experimental Drug,No Intervention No treatment

Sodium Polynucleotide,No treatment

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Immediate post excision patient, size more than 2 cm, aged upper 18 years, 2. Healthy individual, 3. Capable to visit at OPD and follow the method, 4. Agree with informed consent, 5.Fitzpatrick skin type III-IV

Exclusion criteria

Exclusion criteria: 1. Allergic to Sodium polynucleotide, 2. Using NSIAD, anticoagulants, immunosuppressive drugs, 3. Phobia from injection, 4. The presence of inflammation or infection on the skin around the site of the injection, 5. Pregnancy, 6. Not suspected precancerous lesion

Design outcomes

Primary

Measure	Time frame
Scar volume at 1,4,8,12 weeks after end of the intervention Antera3D,Vascularity at 1,4,8,12 weeks after end of the intervention Antera3D,Thickness/height at 1,4,8,12 weeks after end of the intervention Vancouver scar scale,Pliability at 1,4,8,12 weeks after end of the intervention Vancouver scar scale,Vascularity at 1,4,8,12 weeks after end of the intervention Vancouver scar scale,Pigmentation at 1,4,8,12 weeks after end of the intervention Vancouver scar scale,Pigmentation at 1,4,8,12 weeks after end of the intervention Antera3D	—

Measure

Time frame

Scar volume at 1,4,8,12 weeks after end of the intervention Antera3D,Vascularity at 1,4,8,12 weeks after end of the intervention Antera3D,Thickness/height at 1,4,8,12 weeks after end of the intervention Vancouver scar scale,Pliability at 1,4,8,12 weeks after end of the intervention Vancouver scar scale,Vascularity at 1,4,8,12 weeks after end of the intervention Vancouver scar scale,Pigmentation at 1,4,8,12 weeks after end of the intervention Vancouver scar scale,Pigmentation at 1,4,8,12 weeks after end of the intervention Antera3D

—

Secondary

Measure	Time frame
Satisfied score at 1,4,8,12 weeks after end of the intervention 5-point Global assessment score,Itchness at 1,4,8,12 weeks after end of the intervention Visual analogue scale,Pain at 1,4,8,12 weeks after end of the intervention Visual analogue scale	—

Countries

Thailand

Contacts

Public ContactWanida Laorenu

Thammasat university

da.wnd@hotmail.com0951989259

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026